Quinazolinon derivatives for the treatment of neoplastic, parasitic and neurodegenerative diseases
https://doi.org/10.17650/1726-9784-2017-16-3-32-42
Abstract
In this review we discuss some biological activities of quinazolinon derivatives. The derivatives of quinazolinon possess their activity by binding to some proteins important for the survival, proliferation and metastasis of tumor cells. There are grounds to initiate clinical trials of these substances to create new treatment protocols for a wide range of cancer diseases, several parasitic diseases, and certain neurodegenerative diseases.
About the Authors
D. S. Khachatryan
Institute of Chemical Reagents and High Purity Chemical Substances (IREA)
Russian Federation
Russian Federation
V. A. Misyurin
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
M. A. Baryshnikova
Institute of Chemical Reagents and High Purity Chemical Substances (IREA); N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
N. V. Golubtsova
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
A. V. Kolotaev
Institute of Chemical Reagents and High Purity Chemical Substances (IREA)
Russian Federation
Russian Federation
K. R. Matevosyan
Dmitry Mendeleev University of Chemical Technology of Russia
Russian Federation
Russian Federation
References
1. Alaimo R.J., Russell H.E. Antibacterial 2.3-dihydro-2-(5-nitro-2-thienyl) - quinazolin-4(1H) - ones. J Med Chem 1972;15(3):335-6. PMID: 4621761.
2. Bonola G., Da Re P., Magistretti M.J. et al. 1-aminoacyl-2,3-dihydro-4(1H) - quinazolinone derivatives with choleretic and antifibrillatory activity. J Med Chem 1968;11(6):1136-9. PMID: 5680025.
3. Levin J.I., Chan P.S., Bailey T. et al. The synthesis of 2,3-dihydro-4(1H) - quinazolinone angiotensin II receptor antagonists Bioorg. Med Chem Lett 1994;4:1141-6.
4. Okumura K., Oine T., Yamada Y. et al. 4-oxo-1,2,3,4-tetrahydroquinazolines. I. Syntheses and pharmacological properties of 2-methyl-3-aryl-4-oxo- 1,2,3,4-tetrahydroquinazolines and their 1-acyl derivatives. J Med Chem 1968;11(2):348-52. PMID: 4385706.
5. Neil G.L., Li L.H., Buskirk H.H., Moxley T.E. Antitumor effects of the antispermatogenic agent, 2.3-dihydro-2-(1-naphthyl) - 4(1H) - quinazolinone(NSC-145669). Cancer Chemother Rep 1972;56(2):163-73. PMID: 5043224.
6. Хачатрян Д.С., Белусь С.К., Мисюрин В.А. Синтез и свойства 1,2-ди-гидро-4(3H)-хиназолинонов. Известия РАН. Серия химическая 2017;6:1044.
7. PubChem Project https://pubchem.ncbi. nlm.nih.gov/
8. Alexandrov V., Brunner D., Hanania T., Leahy E. High-throughput analysis of behavior for drug discovery. Eur J Pharmacol 2015;750:82-9. DOI: 10.1016/j. ejphar. 2014.11.047. PMID: 25592319.
9. Baker J.R., Gamberger D., Mihelcic J.R., Sabljic A. Evaluation of artificial intelligence based models for chemical biodegradability prediction. Molecules 2004;9(12):989-1004. PMID: 18007499.
10. Sikdar N., Banerjee S., Lee K.Y. et al. DNA damage responses by human ELG1 in S phase are important to maintain genomic integrity. Cell Cycle 2009;8(19):3199-207. DOI: 10.4161/cc.8.19.9752. PMID: 19755857.
11. Heo J., Li J., Summerlin M. et al. TDP1 promotes assembly of non-homologous end joining protein complexes on DNA. DNA Repair(Amst)2015;30:28-37. DOI: 10.1016/j.dnarep. 2015.03.003. PMID: 25841101.
12. Клаан Н.К., Пронина Т. А., Акиньшина Л.П., Решетникова В. В. Ядерный фактор каппа В (NF-kB) в качестве мишени для действия природных противоопухолевых соединений. Российский биотерапевтический журнал 2014;13(1):3-8.
13. Liu P.F., Leung C.M., Chang Y.H. et al. ATG4B promotes colorectal cancer growth independent of autophagic flux. Autophagy 2014;10(8):1454-65. DOI: 10.4161/auto. 29556. PMID: 24991826.
14. Qin L., Yang F., Zhou C. et al. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor. J Am Chem Soc 2014;136(52):18023-33. DOI: 10.1021/ja509223m. PMID: 25453499.
15. Мисюрин А.В. Молекулярный патогенез миелопролиферативных заболеваний. Клиническая онкогематология. Фундаментальные исследования и клиническая практика 2009;2(3):211.
16. Barwick K.E., Wright J., Al-Turki S. et al. Defective presynaptic choline transport underlies hereditary motor neuropathy. Am J Hum Genet 2012;91(6):1103-7. DOI: 10.1016/j.ajhg.2012.09.019. PMID: 23141292.
17. Abdul-Ridha A., Lane J.R., Mistry S.N. et al. Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor. J Biol Chem 2014;289(48):33701-11. DOI: 10.1074/jbc.M114.604967. PMID: 25326383.
18. Arning L., Stock A.K., Kloster E. et al. NPY2-receptor variation modulates iconic memory processes. Eur Neuro-psychopharmacol 2014;24(8):1298-302. DOI: 10.1016/j. euroneuro.2014.03.003. PMID: 24709141.
19. Rustgi A.K., Van’t Veer L.J., Bernards R. Two genes encode factors with NF-kappa B- and H2TF1-like DNA-binding properties. Proc Natl Acad Sci USA 1990;87(22):8707-10. PMID: 2247438.
20. Bayrer J.R., Mukkamala S., Sablin E.P. et al. Silencing LRH-1 in colon cancer cell lines impairs proliferation and alters gene expression programs. Proc Natl Acad Sci USA 2015;112(8):2467-72. DOI: 10.1073/pnas. 1500978112. PMID: 25675535.
21. Cichero E., Espinoza S., Gainetdinov R.R. et al. Insights into the structure and pharmacology of the human trace amine-associated receptor 1(hTAAR1): homology modelling and docking studies. Chem Biol Drug Des 2013;81(4):509-16. DOI: 10.1111/cbdd.12018. PMID: 22883051.
22. Gelernter J., Gueorguieva R., Kranzler H.R. et al. Opioid receptor gene(OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 2007;31(4):555-63. DOI: 10.1111/j. 1530-0277.2007.00339.x. PMID: 17374034.
23. McMillan H. J., Worthylake T., Schwartzentruber J. et al. Specific combination of compound heterozygous mutations in 17ß-hydroxysteroid dehydrogenase type 4(HSD17B4) defines a new subtype of D-bifunctional protein deficiency. Orphanet J Rare Dis 2012;7:90. DOI: 10.1186/1750-1172-7-90. PMID: 23181892.
24. Guerra-Calderas L., Gonzalez-Barrios R., Herrera LA. et al. The role of the histone demethylase KDM4A in cancer. Cancer Genet 2015;208(5):215-24. DOI: 10.1016/j.cancergen.2014.11.001. PMID: 25633974.
25. Kang S.G., Maurizi M.R., Thompson M. et al. Crystallography and mutagenesis point to an essential role for the N-terminus of human mitochondrial ClpP. J Struct Biol 2004;148(3):338-52. DOI: 10.1016/j.jsb.2004.07.004. PMID: 15522782.
26. Zhang L., Dai F., Cui L. et al. Novel role for TRPC4 in regulation of macro-autophagy by a small molecule in vascular endothelial cells. Biochim Biophys Acta 2015;1853(2):377-87. DOI: 10.1016/j.bbamcr.2014.10.030. PMID: 25476892.
27. Aliyev A., Soundararajan S., Bucak E. et al. The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer. Surgery 2015;158(4):1089-93; discussion 1093-4. DOI: 10.1016/j.surg.2015.06.023. PMID: 26212344.
28. Horn T., Ivanov I., Di Venere A. et al. Molecular basis for the catalytic inactivity of a naturally occurring nearnull variant of human ALOX15. Biochim Biophys Acta 2013;1831(12):1702-13. DOI: 10.1016/j.bbalip 2013.08.004. PMID: 23958500.
29. Sheedy F.J. Turning 21: Induction of miR-21 as a Key Switch in the Inflammatory Response. Front Immunol. 2015;6:19. DOI: 10.3389/fimmu.2015.00019. eCollection 2015. PMID: 25688245.
30. Jiang Q., Greenberg R.A. Deciphering the BRCA1 Tumor Suppressor Network. J Biol Chem 2015;290(29):17724-32. DOI: 10.1074/jbc.R115.667931. PMID: 26048987.
31. Thangaraju M., Kaufmann S.H., Couch F.J. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 2000;275(43):33487-96. DOI: 10.1074/jbc.M005824200. PMID: 10938285.
32. Esser C., Rannug A. The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacol Rev 2015;67(2):259-79. DOI: 10.1124/pr.114.009001. PMID: 25657351.
33. Zhang Y., Molavi O., Su M., Lai R. The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma. BMC Cancer 2014;14:791. DOI: 10.1186/1471-2407-14-791. PMID: 25355139.
34. Kahali B., Yu J., Marquez S.B. et al. The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors. Oncotarget 2014;5(10):3316-32. DOI: 10.18632/oncotarget. 1945. PMID: 24913006.
35. Lanzino M., Maris P., Sirianni R. et al. DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation. Cell Death Dis 2013;4: e724. DOI: 10.1038/ cddis. 2013.235. PMID: 23846226.
36. Jiang H.L., Xu D., Yu H. et al. DAX-1 inhibits hepatocellular carcinoma proliferation by inhibiting ß-catenin transcriptional activity. Cell Physiol Biochem 2014;34(3):734-42. DOI: 10.1159/000363038. PMID: 25171651.
37. Yu Y., Prassas I., Dimitromanolakis A., Diamandis E.P. Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics. J Biol Chem 2015;290(29):17762-75. DOI: 10.1074/jbc.M115.643551. PMID: 26032414.
38. Walker F., Nicole P., Jallane A. et al. Kallikrein-related peptidase 7(KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer. Biol Chem 2014;395(9):1075-86. DOI: 10.1515/hsz-2014-0142. PMID: 25153388.
39. Iakovlev V., Siegel E.R., Tsao M.S., Haun R.S. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2012;21(7):1135-42. DOI: 10.1158/1055-9965.EPI-11-1079. PMID: 22573795.
40. Innamaa A., Jackson L., Asher V. et al. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma. Anticancer Res 2013;33(4):1401-8. PMID: 23564779.
41. Juhasz G., Hullam G., Eszlari N. et al. Brain galanin system genes interact with life stresses in depression-related phenotypes. Proc Natl Acad Sci USA 2014;111(16):E1666-73. DOI: 10.1073/pnas.1403649111. PMID: 24706871.
42. Bench A.J., Li J., Huntly B.J. et al. Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies. Br J Haematol 2004;127(5):509-18. DOI: 10.1111/j.1365-2141.2004.05278.x. PMID: 15566354.
43. Nowak R., Woszczynski M., Siedlecki J.A. Changes in the DNA polymerase beta gene expression during development of lung, brain, and testis suggest an involvement of the enzyme in DNA recombination. Exp Cell Res 1990;191(1):51-6. PMID: 2226650.
44. Hinz J.M. Impact of abasic site orientation within nucleosomes on human APE1 endonuclease activity. Mutat Res 2014;766-767:19-24. DOI: 10.1016/j.mrfmmm.2014.05.008. PMID: 25083139.
45. Yue L., Huang Z.M., Fong S. et al. Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. Melanoma Res 2015;25(2):138-48. DOI: 10.1097/ CMR.0000000000000144. PMID: 25643237.
46. Li W., Zhang S.L., Wang N. et al. Blockade of T-type Ca(2+) channels inhibits human ovarian cancer cell proliferation. Cancer Invest 2011;29(5):339-46. DOI: 10.3109/07357907.2011.568565. PMID: 21438841.
47. Fujii R., Yoshida H., Fukusumi S. et al. Identification of a neuropeptide modified with bromine as an endogenous ligand for GPR7. J Biol Chem 2002;277(37):34010-6. DOI: 10.1074/ jbc.M205883200. PMID: 12118011.
48. Medina P.P., Romero O.A., Kohno T. et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 2008;29(5): 617-22. DOI: 10.1002/humu.20730. PMID: 18386774.
49. Pulkkinen V., Ezer S., Sundman L. et al. Neuropeptide S receptor 1(NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors. Virchows Arch 2014;465(2):173-83. DOI: 10.1007/ s00428-014-1602-x. PMID: 24915894.
50. Solinski H.J., Zierler S., Gudermann T., Breit A. Human sensory neuron-specific Mas-related G protein-coupled receptors-X1 sensitize and directly activate transient receptor potential cation channel V1 via distinct signaling pathways. J Biol Chem 2012;287(49):40956-71. DOI: 10.1074/jbc.M112.408617. PMID: 23074220.
51. Zeng B., Yuan C., Yang X. et al. TRPC channels and their splice variants are essential for promoting human ovarian cancer cell proliferation and tumorigenesis. Curr Cancer Drug Targets 2013;13(1):103-16. PMID: 22920441.
52. Manna J.D., Wepy J.A., Hsu K.L. et al. Identification of the major prostaglandin glycerol ester hydrolase in human cancer cells. J Biol Chem 2014;289(49):33741-53. DOI: 10.1074/jbc.M114.582353. PMID: 25301951.
53. Sparta A.M., Bressanin D., Chiarini F. et al. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. Cell Cycle 2014;13(14):2237-47. DOI: 10.4161/cc.29267. PMID: 24874015.
54. Alberts B., Johnson A., Lewis J. et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science, 2002. 877 p.
55. Kamath J. Cancer-related fatigue, inflammation and thyrotropin-releasing hormone. Curr Aging Sci 2012;5(3):195-202. PMID: 23387883.
56. Jia M., Souchelnytskyi N., Hellman U. et al. Proteome profiling of immortalization-to-senescence transition of human breast epithelial cells identified MAP2K3 as a senescence-promoting protein which is downregulated in human breast cancer. Proteomics Clin Appl 2010;4(10-11):816-28. DOI: 10.1002/prca. 201000006. PMID: 21137025.
57. Barbero P., Bittova L., Pfeffer S.R. Visualization of Rab9-mediated vesicle transport from endosomes to the trans-Golgi in living cells. J Cell Biol 2002;156(3):511-8. DOI: 10.1083/jcb.200109030. PMID: 11827983.
58. Yu X.H., Jiang N., Yao P.B. et al. NPC1, intracellular cholesterol trafficking and atherosclerosis. Clin Chim Acta 2014;429:69-75. DOI: 10.1016/j.cca.2013.11.026. PMID: 24296264.
59. Cho S., Moon H., Loh T.J. et al. 3’ Splice site sequences of spinal muscular atrophy related SMN2 pre-mRNA include enhancers for nearby exons. Sci World J 2014;2014:617842. PMID: 24616638.
60. Mitchell J.C., Constable R., So E. et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol Commun 2015;3:36. DOI: 10.1186/s40478-015-0212-4. PMID: 26108367.
61. Michel V., Bakovic M. The ubiquitous choline transporter SLC44A1. Cent Nerv Syst Agents Med Chem 2012;12(2):70-81. PMID: 22483272.
62. Beutin L. Emerging enterohaemorrhagic Escherichia coli, causes and effects of the rise of a human pathogen. J Vet Med B Infect Dis Vet Public Health 2006;53(7):299-305. DOI: 10.1111/j.1439-0450.2006.00968.x. PMID: 16930272.
63. Zgiby S.M., Thomson G.J., Qamar S., Berry A. Exploring substrate binding and discrimination in fructose1, 6-bisphosphate and tagatose 1,6-bisphosphate aldolases. Eur J Biochem 2000;267(6):1858-68. PMID: 10712619.
64. Владимирская Е.Б. Апоптоз и его роль в регуляции клеточного равновесия. Клиническая лабораторная диагностика 2002;11:25-32.
65. Владимирская Е.Б. Апоптоз в регуляции клеточного равновесия и формировании опухолевого роста. Вопросы гематологии, онкологии и иммунопатологии в педиатрии 2003;2(1):5.
66. Мисюрина А.Е., Мисюрин В.А., Барях Е.А. и др. Роль экспрессии генов c-MYC, BCL2 и BCL6 в патогенезе диффузной В-крупноклеточной лимфомы. Клиническая онкогематология. Фундаментальные исследования и клиническая практика 2014;7(4):511-20.
67. Verbeke C.S., Wenthe U., Zentgraf H. Fas ligand expression in the germinal centre. J Pathol 1999;189(2):155-60. DOI: 10.1002/(SICI)1096-9896 (199910)189:2<155::AID-PATH442>3.0.CO;2-9. PMID: 10547568.
68. Мисюрин В.А. Структура и свойства основных рецепторов и лигандов внешнего пути апоптоза. Российский биотерапевтический журнал 2015;14(2):23-30.
69. Agapova L.S., Ivanov A.V., Sablina A.A. et al. P53-dependent effects of RAS oncogene on chromosome stability and cell cycle checkpoints. Oncogene 1999;18(20):3135-42.
70. Keizer H.G., Pinedo H.M., Schuurhuis G.J., Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990;47(2):219-31. PMID: 2203071.
Review
For citations:
Khachatryan D.S., Misyurin V.A., Baryshnikova M.A., Golubtsova N.V., Kolotaev A.V., Matevosyan K.R. Quinazolinon derivatives for the treatment of neoplastic, parasitic and neurodegenerative diseases. Russian Journal of Biotherapy. 2017;16(3):32-42. (In Russ.) https://doi.org/10.17650/1726-9784-2017-16-3-32-42
Views:
557
Email this article 
